Adynovate

BIOLOGICAL4 trials

Sponsors

Takeda, University of Texas Southwestern Medical Center

Conditions

Factor VIIIHemophilia A

Phase 3

A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A

CompletedNCT05707351

TakedaHemophilia A

Start: 2023-03-27End: 2024-09-05Updated: 2025-05-01

Phase 4

POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies

WithdrawnNCT04690322

University of Texas Southwestern Medical CenterFactor VIII, Hemophilia A

Start: 2021-04-15End: 2027-07-01Updated: 2026-04-07

Unknown Phase

ADYNOVATE Drug Use-Results Survey

CompletedNCT03169972

TakedaHemophilia A

Start: 2017-02-01End: 2023-09-15Updated: 2025-02-04

Post Marketing Surveillance Study for ADYNOVATE in South Korea

CompletedNCT03824522

TakedaHemophilia A

Start: 2019-02-25End: 2024-01-05Updated: 2024-02-26

Related Papers

Real-world safety and effectiveness of rurioctocog alfa pegol in 338 patients with hemophilia A in South Korea: A postmarketing surveillance study.

2025-07-09